Enveric Biosciences Presents Compelling Preclinical Data On Lead Compound EB-003 At 7th Neuropsychiatric Drug Summit [Benzinga]
Wednesday, September 25, 2024 1 min read
Key Takeaway: Enveric Biosciences has announced the presentation of its lead compound, EB-003, at the 7th Neuropsychiatric Drug Summit. EB-003, a non-hallucinogenic DMT analog, demonstrated beneficial effects in preclinical models for anxiety and depression. The summit will take place from September 24-26, 2024, in Boston, MA.
Price reaction · baseline $88.236 (2024-09-25T14:08:00.000Z) · hit during market hours · 2 other ENVB headline(s) in the window, move may be shared
day 0 close · peak
+3.8%
Market Sentiment Analysis
POSITIVE FACTORS
EB-003 shows promising results in preclinical models.
The compound is non-hallucinogenic, making it a safer alternative.
Presentation at a significant summit highlights its potential.
Full Press Release Details
Enveric Biosciences ENVB recently announced that research highlighting the Company’s lead compound, EB-003, is being presented at the 7th Neuropsychiatric Drug Summit.
EB-003 is a promising neuroplastogenic and non-hallucinogenic N, N-Dimethyltryptamine (DMT) analog drug candidate that elicited beneficial outcomes in preclinical models of anxiety and depression. The conference is being held at the Hilton Boston Back Bay in Boston, MA on September 24-26, 2024.
Full Article >>
Frequently Asked Questions
What is EB-003?
EB-003 is a non-hallucinogenic DMT analog developed by Enveric Biosciences.
What conditions does EB-003 target?
EB-003 targets anxiety and depression based on preclinical studies.
Where is the Neuropsychiatric Drug Summit held?
The summit is held at the Hilton Boston Back Bay in Boston, MA.
When will the summit take place?
The summit is scheduled for September 24-26, 2024.